538 related articles for article (PubMed ID: 33298621)
1. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
5. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
8. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
9. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.
Puzanov I; Subramanian P; Yatsynovich YV; Jacobs DM; Chilbert MR; Sharma UC; Ito F; Feuerstein SG; Stefanovic F; Switzer B; Hicar MD; Curtis AB; Spangenthal EJ; Dy GK; Ernstoff MS; Vachhani P; Page BJ; Agrawal N; Khunger A; Kapoor A; Hattoum A; Schentag JJ
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34162715
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports.
Wang C; Zhao G; Zhang Z; Yang L; Liu S; Li G; Wang H; Huang J; Wang S; Li N
Front Immunol; 2023; 14():1275254. PubMed ID: 37876928
[TBL] [Abstract][Full Text] [Related]
15. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature.
Nakagomi Y; Tajiri K; Shimada S; Li S; Inoue K; Murakata Y; Murata M; Sakai S; Sato K; Ieda M
Front Pharmacol; 2022; 13():884776. PubMed ID: 35645839
[No Abstract] [Full Text] [Related]
17. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis.
Power JR; Alexandre J; Choudhary A; Ozbay B; Hayek SS; Asnani A; Tamura Y; Aras M; Cautela J; Thuny F; Gilstrap L; Arangalage D; Ewer S; Huang S; Deswal A; Palaskas NL; Finke D; Lehmann LH; Ederhy S; Moslehi J; Salem JE;
Arch Cardiovasc Dis; 2022 May; 115(5):315-330. PubMed ID: 35595646
[TBL] [Abstract][Full Text] [Related]
18. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.
Thavendiranathan P; Zhang L; Zafar A; Drobni ZD; Mahmood SS; Cabral M; Awadalla M; Nohria A; Zlotoff DA; Thuny F; Heinzerling LM; Barac A; Sullivan RJ; Chen CL; Gupta D; Kirchberger MC; Hartmann SE; Weinsaft JW; Gilman HK; Rizvi MA; Kovacina B; Michel C; Sahni G; González-Mansilla A; Calles A; Fernández-Avilés F; Mahmoudi M; Reynolds KL; Ganatra S; Gavira JJ; González NS; García de Yébenes Castro M; Kwong RY; Jerosch-Herold M; Coelho-Filho OR; Afilalo J; Zataraín-Nicolás E; Baksi AJ; Wintersperger BJ; Calvillo-Arguelles O; Ederhy S; Yang EH; Lyon AR; Fradley MG; Neilan TG
J Am Coll Cardiol; 2021 Mar; 77(12):1503-1516. PubMed ID: 33766256
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.
Matzen E; Bartels LE; Løgstrup B; Horskær S; Stilling C; Donskov F
Cardiooncology; 2021 Aug; 7(1):27. PubMed ID: 34365980
[TBL] [Abstract][Full Text] [Related]
20. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis.
Cadour F; Cautela J; Rapacchi S; Varoquaux A; Habert P; Arnaud F; Jacquier A; Meilhac A; Paganelli F; Lalevée N; Scemama U; Thuny F
Radiology; 2022 Jun; 303(3):512-521. PubMed ID: 35230185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
